One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Next-Generation Sequencing (NGS) Market

[ 英語タイトル ] Next-Generation Sequencing (NGS) Market by Product (NovaSeq, NextSeq, Sequel, Nanopore), Consumables, Bioinformatics, Services (Exome, RNA, DeNovo), Technology (Ion, SMRT), Application (Diagnostics, Cancer), End User (Academia) - Global Forecasts to 2024


Product Code : MNMHC00110160
Survey : MarketsandMarkets
Publish On : February, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5650 / Question Form
5 User USD6650 / Question Form
Enterprise User USD10000 / Question Form

[Report Description]

“Global Next-generation Sequencing Market to Register a CAGR of 19.2% from 2018 to 2024”

The global next-generation sequencing market is projected to reach USD 16.35 billion by 2024 from USD 5.70 billion in 2018, at a CAGR of 19.2%. Factors such as advancements in NGS platforms, declining NGS capital cost coupled with decreasing cost of sequencing, improving regulatory & reimbursement scenario for NGS-based diagnostic tests, initiatives from government & private bodies for large-scale sequencing projects, and increasing application of NGS in precision medicine & molecular diagnostics are expected to propel the growth of this market. However, end-user budget constraints in developing nations are expected to restrain the growth of the next-generation sequencing market in the forecast period.

“Sequencing by Synthesis Segment to Dominate the NGS Market, by Technology, in 2018”
The next-generation sequencing market, by technology, is segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, nanopore sequencing, and other sequencing technologies. The sequencing by synthesis segment is expected to command the largest share of the next-generation sequencing market in 2018. The large share of this segment can be attributed to the continuous advancements in SBS technology-based consumables and NGS bioinformatics solutions as well as the launch of advanced cost- & time-efficient platforms based on SBS technology.

“Hospitals & Clinics Segment to Register the Highest CAGR During 2018–2024”
On the basis of end user, the next-generation sequencing market is segmented into academic institutes & research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. The hospitals & clinics segment is estimated to witness the highest growth rate during the forecast period. The high growth in this segment can be attributed to the development of advanced NGS-based diagnostic solutions and growing number of agreements between companies and hospitals for developing advanced tests and products catering to the specific needs of hospitals and clinics.

“The NGS Market in the APAC is Projected to Witness the Highest Growth Rate During the Forecast Period”
The next-generation sequencing market in the Asia Pacific is expected to witness the highest CAGR from 2018 to 2024. Factors such as increasing financial support from public as well as private agencies for NGS based research and diagnostics, increasing number of NGS-based research projects, increasing awareness about precision medicine, and high incidence of chronic diseases in the region are driving the growth of the next-generation sequencing market in the APAC region.

Breakdown of supply-side primary interviews: by company type, designation, and region:
• By Company Type: Tier 1 - 40%, Tier 2 - 25%, and Tier 3 - 36%
• By Designation: C-level - 43%, Director-level - 22%, and Others - 35%
• By Region: North America - 37%, Europe - 12%, APAC - 41%, and RoW - 10%

The key players in the next-generation sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Pacific Biosciences of California, Inc. (US), BGI (China), PerkinElmer (US), Agilent Technologies (US), QIAGEN N. V. (Germany), Macrogen Inc. (South Korea), Oxford Nanopore Technologies, Ltd. (UK), and Eurofins Scientific (Luxembourg).

Research Coverage
This report studies the next-generation sequencing market based on product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on business strategies adopted by the major players in the next-generation sequencing market. The report analyzes the next-generation sequencing market based on product & service, technology, application, end user, and region

• Service Launches: Insights on the research and development activities and product & service launches in the next-generation sequencing market

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various next-generation sequencing types across regions

• Market Diversification: Exhaustive information about recent developments, and investments in the next-generation sequencing market

• Competitive Assessment: In-depth assessment of market ranking, strategies, and products of leading players in the next-generation sequencing market

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
2.1.1 SECONDARY DATA 24
2.1.1.1 Key data from secondary sources 24
2.1.2 PRIMARY DATA 25
2.1.2.1 Breakdown of primaries 25
2.1.2.2 Key data from primary sources 26
2.2 MARKET SIZE ESTIMATION 27
2.2.1 BOTTOM-UP APPROACH 27
2.2.2 TOP-DOWN APPROACH 28
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 29
2.4 ASSUMPTIONS FOR THE STUDY 30
3 EXECUTIVE SUMMARY 31
4 PREMIUM INSIGHTS 35
4.1 NEXT-GENERATION SEQUENCING (NGS): MARKET OVERVIEW 35
4.2 NGS MARKET, BY PRODUCT & SERVICE, 2018 VS. 2024 35
4.3 NGS MARKET, BY TECHNOLOGY, 2018 VS. 2024 (USD MILLION) 36
4.4 NGS MARKET, BY APPLICATION, 2018 VS. 2024 (USD MILLION) 36
4.5 NGS MARKET, BY END USER AND REGION, 2018 37
5 MARKET OVERVIEW 38
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 DRIVERS 39
5.2.1.1 Advancements in NGS platforms 39
5.2.1.1.1 iSeq 39
5.2.1.1.2 Ion GeneStudio S5 39
5.2.1.2 Declining costs 39
5.2.1.3 Improving regulatory & reimbursement scenario for NGS-based diagnostic tests 41
5.2.2 RESTRAINTS 42
5.2.2.1 End-user budget constraints in developing nations 42
5.2.3 OPPORTUNITIES 42
5.2.3.1 Initiatives from government & private bodies for large-scale sequencing projects 42
5.2.3.2 Application of NGS in precision medicine & molecular diagnostics 43
5.2.3.3 NGS data analysis using Big Data 43
5.2.4 CHALLENGES 44
5.2.4.1 Interpretation of complex data from NGS platforms 44
5.2.4.2 Ethical issues 44
5.2.5 INDUSTRY TRENDS 44
5.2.5.1 Reduction in platform footprint and the development of portable sequencing technology 44
5.2.5.2 Partnerships and Collaborations for technological advancements in NGS 45
5.2.5.3 Conferences and workshops increasing awareness on NGS products and services 46
6 NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE 47
6.1 INTRODUCTION 48
6.2 PRE-SEQUENCING PRODUCTS & SERVICES 49
6.2.1 SAMPLE PREPARATION 50
6.2.1.1 DNA fragmentation, end repair, A-tailing, and size selection 50
6.2.1.2 Library preparation & target enrichment 51
6.2.1.3 Quality control 53
6.3 NGS CONSUMABLES, PLATFORMS, & SERVICES FOR PLATFORMS 54
6.3.1 NGS CONSUMABLES 55
6.3.2 NGS PLATFORMS 55
6.3.2.1 Illumina 57
6.3.2.1.1 HiSeq series 58
6.3.2.1.2 HiSeq X ten & HiSeq X five 58
6.3.2.1.3 MiSeq series 59
6.3.2.1.4 NextSeq 500 60
6.3.2.1.5 MiniSeq 61
6.3.2.1.6 NovaSeq 62
6.3.2.2 Thermo fisher scientific 63
6.3.2.2.1 Ion PGM 64
6.3.2.2.2 Ion proton 64
6.3.2.2.3 Ion S5 & S5 XL 65

6.3.2.3 Pacific biosciences 66
6.3.2.3.1 PacBio RS II 67
6.3.2.3.2 Sequel system 67
6.3.2.4 Oxford nanopore technologies 68
6.3.2.5 Other next-generation sequencing platforms 69
6.3.3 SERVICES FOR NGS PLATFORMS 70
6.4 SEQUENCING SERVICES 70
6.4.1 EXOME & TARGETED RE-SEQUENCING AND CUSTOM PANELS 72
6.4.2 RNA-SEQ 72
6.4.3 WHOLE-GENOME SEQUENCING & DE NOVO SEQUENCING 73
6.4.4 OTHER SEQUENCING SERVICES 74
6.5 NGS DATA ANALYSIS, STORAGE, AND MANAGEMENT (BIOINFORMATICS) 75
6.5.1 NGS DATA ANALYSIS SOFTWARE & WORKBENCHES 76
6.5.2 NGS DATA ANALYSIS SERVICES 76
6.5.3 NGS STORAGE, MANAGEMENT, AND CLOUD COMPUTING SOLUTIONS 77
7 NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY 78
7.1 INTRODUCTION 79
7.2 SEQUENCING BY SYNTHESIS 81
7.3 ION SEMICONDUCTOR SEQUENCING 82
7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING 83
7.5 NANOPORE SEQUENCING 84
7.6 OTHER SEQUENCING TECHNOLOGIES 85
8 NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION 86
8.1 INTRODUCTION 87
8.2 DIAGNOSTICS 88
8.2.1 CANCER DIAGNOSTICS 91
8.2.2 INFECTIOUS DISEASE DIAGNOSTICS 92
8.2.3 REPRODUCTIVE HEALTH DIAGNOSTICS 93
8.2.4 OTHER DIAGNOSTIC APPLICATIONS 93
8.3 DRUG DISCOVERY 94
8.4 AGRICULTURAL & ANIMAL RESEARCH 95
8.5 OTHER APPLICATIONS 96
9 NEXT-GENERATION SEQUENCING MARKET, BY END USER 98
9.1 INTRODUCTION 99
9.2 ACADEMIC INSTITUTES & RESEARCH CENTERS 100
9.3 HOSPITALS & CLINICS 101
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 102
9.5 OTHER END USERS 103
10 NEXT-GENERATION SEQUENCING MARKET, BY REGION 105
10.1 INTRODUCTION 106
10.2 NORTH AMERICA 107
10.2.1 US 113
10.2.2 CANADA 114
10.3 EUROPE 115
10.3.1 GERMANY 122
10.3.2 UK 123
10.3.3 FRANCE 124
10.3.4 SPAIN 125
10.3.5 ITALY 126
10.3.6 NETHERLANDS 126
10.3.7 ROE 128
10.4 ASIA PACIFIC 128
10.4.1 CHINA 135
10.4.2 JAPAN 136
10.4.3 INDIA 137
10.4.4 REST OF ASIA PACIFIC 138
10.5 REST OF THE WORLD 139
11 COMPETITIVE LANDSCAPE 146
11.1 OVERVIEW 146
11.2 MARKET SHARE ANALYSIS 147
11.3 COMPETITIVE SITUATION AND TRENDS 149
11.3.1 PRODUCT LAUNCHES, PRODUCT ENHANCEMENTS, AND SERVICE LAUNCHES 149
11.3.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, AND CONTRACTS 150
11.3.3 MERGERS AND ACQUISITIONS 151
11.3.4 EXPANSIONS 152
12 COMPANY PROFILE 153
12.1 10X GENOMICS 153
12.1.1 BUSINESS OVERVIEW 153
12.1.2 PRODUCTS OFFERED 153
12.1.3 RECENT DEVELOPMENTS (2015-2018) 155
12.1.4 MNM VIEW 156
12.2 AGILENT TECHNOLOGIES, INC. 157
12.2.1 BUSINESS OVERVIEW 157
12.2.2 PRODUCTS OFFERED 158
12.2.3 RECENT DEVELOPMENTS (2015-2018) 163
12.2.4 MNM VIEW 164

12.3 BECKMAN COULTER (A SUBSIDIARY OF DANAHER) 165
12.3.1 BUSINESS OVERVIEW 165
12.3.2 PRODUCTS OFFERED 166
12.3.3 RECENT DEVELOPMENTS (2015-2018) 167
12.3.4 MNM VIEW 167
12.4 BECTON, DICKINSON AND COMPANY 168
12.4.1 BUSINESS OVERVIEW 168
12.4.2 PRODUCTS OFFERED 169
12.4.3 RECENT DEVELOPMENTS (2015-2018) 169
12.4.4 MNM VIEW 169
12.5 BGI 170
12.5.1 BUSINESS OVERVIEW 170
12.5.2 PRODUCTS OFFERED 170
12.5.3 SERVICES OFFERED 170
12.5.4 MNM VIEW 173
12.6 EUROFINS SCIENTIFIC 174
12.6.1 BUSINESS OVERVIEW 174
12.6.2 SERVICES OFFERED 175
12.6.3 RECENT DEVELOPMENTS (2015-2018) 176
12.6.4 MNM VIEW 177
12.7 F. HOFFMANN-LA ROCHE AG 178
12.7.1 BUSINESS OVERVIEW 178
12.7.2 PRODUCTS OFFERED 179
12.7.3 RECENT DEVELOPMENTS (2015-2018) 181
12.7.4 MNM VIEW 182
12.8 GENEWIZ 183
12.8.1 BUSINESS OVERVIEW 183
12.8.2 SERVICES OFFERED 183
12.8.3 RECENT DEVELOPMENTS (2015-2018) 183
12.8.4 MNM VIEW 184
12.9 ILLUMINA, INC. 185
12.9.1 BUSINESS OVERVIEW 185
12.9.2 PRODUCTS OFFERED 186
12.9.3 SERVICES OFFERED 189
12.9.4 RECENT DEVELOPMENTS (2015-2018) 190
12.9.5 MNM VIEW 192
12.10 MACROGEN, INC. 193
12.10.1 BUSINESS OVERVIEW 193
12.10.2 SERVICES OFFERED 193
12.10.3 RECENT DEVELOPMENTS (2015-2018) 194
12.10.4 MNM VIEW 195

12.11 OXFORD NANOPORE TECHNOLOGIES, LTD. 196
12.11.1 BUSINESS OVERVIEW 196
12.11.2 PRODUCTS OFFERED 196
12.11.3 RECENT DEVELOPMENTS (2015-2018) 197
12.11.4 MNM VIEW 197
12.12 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 198
12.12.1 BUSINESS OVERVIEW 198
12.12.2 PRODUCTS OFFERED 199
12.12.3 SERVICES OFFERED 200
12.12.4 RECENT DEVELOPMENTS (2015-2018) 201
12.12.5 MNM VIEW 202
12.13 PERKINELMER, INC. 203
12.13.1 BUSINESS OVERVIEW 203
12.13.2 PRODUCTS & SERVICES OFFERED 204
12.13.3 RECENT DEVELOPMENTS (2015-2018) 205
12.13.4 MNM VIEW 206
12.14 THERMO FISHER SCIENTIFIC INC. 207
12.14.1 BUSINESS OVERVIEW 207
12.14.2 PRODUCTS AND SERVICES OFFERED 208
12.14.3 RECENT DEVELOPMENTS (2015-2018) 211
12.14.4 MNM VIEW 212
12.15 QIAGEN N.V. 213
12.15.1 BUSINESS OVERVIEW 213
12.15.2 PRODUCTS & SERVICES OFFERED 214
12.15.3 RECENT DEVELOPMENTS (2015-2018) 216
12.15.4 MNM VIEW 218
13 APPENDIX 219
13.1 DISCUSSION GUIDE 219
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 225
13.3 AVAILABLE CUSTOMIZATIONS 227
13.4 RELATED REPORTS 227
13.5 AUTHOR DETAILS 228

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+